Takeda’s (NYSE: TAK ... almost a thousand for a disease like alpha-1 antitrypsin deficiency. After fractionation, you go through a process of purification and viral inactivation.

Takeda, a global biopharmaceutical company with a manufacturing site in Stanton Springs, unveiled its new Biomedical Waste ...

CSL is the biggest plasma-derived therapeutics house, vying with Takeda, Grifols, Octapharma and Baxter ... Along the way the company developed snake antivenom, launched plasma fractionation, produced ...

Most of it is a foam fractionation process that treats and by basically gathering the PFAS and then solidifying it. And then that is disposed of separately. And so these are both portable and ...

The U.S. intravenous immunoglobin market size was valued at USD 7.27 billion in 2024 and is projected to reach USD 14.42 billion by 2033, registering a CAGR of 7.9% from 2024 to 2033. The global U.S.

which would leave CSL overinvested in plasma collection and fractionation capacity that will be hard to repurpose. Key segments of haemophilia and hereditary angioedema are currently facing ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

On Monday, Protagonist Therapeutics, Inc. (NASDAQ:PTGX) and Takeda Pharmaceutical Co Ltd (NYSE:TAK) released topline results for the Phase 3 VERIFY study of rusfertide for polycythemia vera.